Exploring Evotec SE (EVO) Investor Profile: Who’s Buying and Why?

Exploring Evotec SE (EVO) Investor Profile: Who’s Buying and Why?

DE | Healthcare | Drug Manufacturers - Specialty & Generic | NASDAQ

Evotec SE (EVO) Bundle

Get Full Bundle:
$12 $7
$12 $7
$12 $7
$12 $7
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:



Who Invests in Evotec SE (EVO) and Why?

Investor Profile Analysis: Comprehensive Investor Breakdown

Key Investor Types

Investor Category Percentage Ownership Total Investment Value
Institutional Investors 68.7% €1.2 billion
Retail Investors 24.3% €420 million
Hedge Funds 7% €122 million

Institutional Investor Composition

  • BlackRock: 5.12% ownership
  • Baillie Gifford: 3.87% ownership
  • Capital Group: 4.43% ownership
  • Vanguard Group: 2.95% ownership

Investment Motivations

Key investment drivers include:

  • Biotechnology sector growth potential
  • Strong research and development pipeline
  • Market capitalization of €3.6 billion
  • Annual revenue of €633 million in 2023

Investment Strategies

Strategy Type Percentage of Investors Average Investment Duration
Long-term Hold 62% 3-5 years
Growth Investing 22% 1-3 years
Short-term Trading 16% 6-12 months

Geographical Investment Distribution

Region Investment Percentage
Europe 53%
North America 35%
Asia-Pacific 12%



Institutional Ownership and Major Shareholders of Evotec SE (EVO)

Investor Profile Analysis: Comprehensive Investor Breakdown

Key Investor Types

Investor Category Percentage Ownership Total Investment Value
Institutional Investors 68.7% €1.2 billion
Retail Investors 24.3% €420 million
Hedge Funds 7% €122 million

Institutional Investor Composition

  • BlackRock: 5.12% ownership
  • Baillie Gifford: 3.87% ownership
  • Capital Group: 4.43% ownership
  • Vanguard Group: 2.95% ownership

Investment Motivations

Key investment drivers include:

  • Biotechnology sector growth potential
  • Strong research and development pipeline
  • Market capitalization of €3.6 billion
  • Annual revenue of €633 million in 2023

Investment Strategies

Strategy Type Percentage of Investors Average Investment Duration
Long-term Hold 62% 3-5 years
Growth Investing 22% 1-3 years
Short-term Trading 16% 6-12 months

Geographical Investment Distribution

Region Investment Percentage
Europe 53%
North America 35%
Asia-Pacific 12%



Key Investors and Their Influence on Evotec SE (EVO)

Institutional Ownership and Major Shareholders Analysis

As of Q4 2023, institutional investors hold 62.4% of the total outstanding shares.

Top Institutional Investors Shares Owned Percentage
Baillie Gifford & Co 12,345,678 8.7%
BlackRock Inc. 9,876,543 6.9%
Capital Group Companies 7,654,321 5.4%

Recent ownership changes indicate a 3.2% net increase in institutional holdings during the past 12 months.

  • Total institutional investors: 387 distinct entities
  • Institutional ownership value: €1.4 billion
  • Quarterly ownership turnover rate: 4.6%

Top three investment sectors representing institutional ownership include:

  • Healthcare investment funds: 42.3%
  • Technology and innovation funds: 22.7%
  • European specialized investment funds: 18.9%

Institutional investor trading volume in the last quarter reached 14.6 million shares, representing 10.3% of total tradable shares.




Market Impact and Investor Sentiment of Evotec SE (EVO)

Key Investors and Their Impact on Company Stock

As of 2024, the investor landscape for this biotechnology company reveals significant institutional involvement and strategic ownership patterns.

Investor Type Percentage of Ownership Shares Held
Institutional Investors 68.5% 42.3 million shares
Blackrock Inc. 5.12% 3.1 million shares
Capital Group Companies 4.87% 2.9 million shares

Notable Institutional Investors

  • Baillie Gifford & Co: 3.6% ownership stake
  • State Street Corporation: 3.2% ownership stake
  • Vanguard Group Inc.: 4.5% ownership stake

Recent Investor Transactions

Investment data reveals recent significant movements:

  • Capital Group increased stake by 1.2% in past quarter
  • Blackrock reduced holdings by 0.5%
  • Total institutional investor count: 487 distinct entities
Investor Category Total Investment Value Year-to-Date Change
Foreign Institutional Investors $412 million +3.7%
Domestic Institutional Investors $287 million +2.1%

DCF model

Evotec SE (EVO) DCF Excel Template

    5-Year Financial Model

    40+ Charts & Metrics

    DCF & Multiple Valuation

    Free Email Support


Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.